Longevity Health Holdings, Inc. announced a significant merger with THPlasma, capturing substantial market interest and boosting the company's stock prices.
Merger Details
The merger between Longevity Health Holdings and THPlasma marks a strategic expansion into the plasma collection industry. Valued at $59 million with an additional $20 million earnout, this merger represents a pivotal move for Longevity into a profitable sector. Following the merger, George Chi will become Co-Chairman and CEO, while Rajiv Shukla will serve as Executive Chairman.
Financials of THPlasma
THPlasma has established itself as a rapidly growing company, securing guaranteed revenues through long-term sales contracts. Estimated revenue for FY2025 is projected at $10 million with $2 million EBITDA, scaling up to $32 million in revenue for FY2026. This underscores the growth and profitability potential of the company, making it an attractive partner for Longevity.
Market Response
The market reacted positively to the merger news, with Longevity stocks surging 134% in premarket trading. Investors demonstrated confidence in the strategic rationale behind the merger, particularly given THPlasma’s established profitability and reliable revenue streams. Longevity's current market capitalization stands at approximately $2.656 million, with trading volume in premarket reaching 22,149 shares.
The merger between Longevity Health and THPlasma opens new opportunities for both companies in the lucrative plasma collection sector. The market's positive reaction underscores a strong investor interest in this merger.
